Processing is complete on material from Red Eye; Nicola Mining awaits test results before sale.

TD Cowen maintained a Buy rating on Visteon with a $131 price target, suggesting a 60.3% upside from the Oct 22 close. The firm cited strong revenue growth prospects and undervaluation at 4x EV/EBITDA, supported by a robust pipeline and net cash balance.

TD Cowen kept a Buy rating on Union Pacific (UNP) with a $328 price target, suggesting a 10% upside from the Oct 22 close. The company reported a 6% YoY increase in carloads and a 13% rise in domestic intermodal volumes, with expectations of continued growth. UNP maintains a high-single digit EPS growth outlook for 2026, citing operational efficiency and pricing power.

Scotiabank raised its price target for FirstService Corp (FSV) to $175 from $170, citing 2027 growth outlook. The stock trades at $143.97, near InvestingPro’s Fair Value estimate. Q3 results met expectations, with organic growth expected in 2027 but earnings may be limited by higher interest costs. FSV trades at 13x 2027 EV/EBITDA, below its historical average of 18x. The company has raised dividends for 11 consecutive years.

Novartis (NVS) reported that Kisqali, combined with endocrine therapy, reduced the risk of death by 19% in early breast cancer patients over six years, according to the NATALEE trial. The study showed continued improvement in invasive disease-free survival and fewer metastatic recurrences. Novartis plans to present the results at ESMO 2026. NVS stock closed at $156.27, up 1.52%.

TD Cowen kept a Buy rating on Norfolk Southern (NSC) with a $379 price target, suggesting a 12.1% upside. The company reported strong Q3 results, with adjusted EPS of $3.62, beating estimates. It also showed stable demand in key markets, like chemicals and metals, despite diesel fuel headwinds.

Tango Therapeutics (TNGX) reported 82% response rate for vopimetostat + daraxonrasib in pancreatic cancer. Plans Phase 3 trial in 2027. Stock down 8.88% in pre-market.